NMN Supplementation for Metabolic Diseases

(VAN Trial)

Overseen By Samuel Klein, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Washington University School of Medicine

Must not be taking: Niacin, Nicotinamide, Vitamin B3

Disqualifiers: Women with menses, High caffeine, Unstable weight, others

Compensation: Varies

Number of Visits: Unknown

Duration: 16 weeks

56 Participants Needed

Trial Summary

What is the purpose of this trial?

The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

Research Team

Samuel Klein, MD

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for adults with a BMI between 25.0-50.0 kg/m² who have prediabetes, indicated by certain blood sugar levels or insulin resistance scores. It's not open to women who are menstruating, people taking vitamin B3 supplements unless they stop them before and during the study, or those consuming more than two cups of coffee daily unless they can quit without withdrawal symptoms.

Inclusion Criteria

You have a body mass index (BMI) between 25 and 34.9.

I have prediabetes based on my glucose tolerance test or HbA1C levels.

Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.

Exclusion Criteria

I drink more than 2 cups of coffee or similar daily or get headaches if I stop.

Unstable weight (>3% change during the last 2 months before entering the study)

I am a woman who still has menstrual periods.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive NMN supplementation or placebo for at least 16 weeks

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Placebo
• Treatment

Trial Overview The study is testing if NMN (a compound that might improve metabolic functions) has positive effects on humans as it does in rodents. Participants will either receive NMN supplementation or a placebo to compare outcomes between the treated group and the control group.

Participant Groups

Group I: NMN supplementation Experimental Treatment 1 Intervention

At least 16 weeks of NMN.

Group II: Placebo Placebo Group 1 Intervention

At least 16 weeks of placebo.

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials

2,027

Recruited

2,353,000+

United States Department of Defense

Collaborator

Trials

940

Recruited

339,000+